文献速递肝病

原发性硬化性胆管炎患者结局相关因素及风险评分系统的开发与验证

Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System.
PubMed 文献 · Hepatology · 2019-03-04

研究基于英国PSC研究队列1001例患者,识别预测肝移植或死亡的临床因素,并开发与验证短期和长期结局风险评分。两个评分系统区分度良好,C统计量分别为0.81和0.80,并在外部队列451例中验证,表现优于Mayo Clinic评分和APRI评分。

要点

  • 诊断后1年碱性磷酸酶≥2.4倍正常上限预测10年结局,中位无移植生存63个月对比108个月。
  • 基于年龄、胆红素、碱性磷酸酶、白蛋白、血小板、肝外胆道疾病及静脉曲张出血的评分预测2年和10年结局。
  • UK-PSC风险评分外部验证C统计量0.75,优于Mayo Clinic评分(0.75)和APRI评分(0.63)。

核心结论

  • 基于大型代表性PSC队列的临床评估,加深了对临床风险标志物的理解,并报告了用于识别最可能死亡或需肝移植患者的真实世界评分系统的开发与验证。

研究设计与样本

  • 分析英国PSC研究队列招募的1001例患者,通过Cox比例风险分析和C统计量评估临床变量与2年和10年结局的关联,生成短期和长期结局预测风险评分,并在总计451例患者的两个独立队列中验证。

主要发现

  • 推导队列中36%的患者在累计随访7904年期间接受肝移植或死亡。
  • 诊断后1年血清碱性磷酸酶至少2.4倍正常上限预测10年结局(风险比[HR]=3.05;C=0.63;中位无移植生存63个月对比108个月;P<0.0001)。
  • 肝外胆道疾病的存在预测10年结局(HR=1.45;P=0.01)。
  • 基于年龄、胆红素、碱性磷酸酶、白蛋白、血小板、肝外胆道疾病及静脉曲张出血的两个风险评分系统预测2年和10年结局,区分度良好(C统计量分别为0.81和0.80)。
  • 两个UK-PSC风险评分在外部队列中验证良好,表现优于Mayo Clinic评分和天冬氨酸氨基转移酶与血小板比率指数(APRI)评分(C统计量分别为0.75和0.63)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

We sought to identify factors that are predictive of liver transplantation or death in patients with primary sclerosing cholangitis (PSC), and to develop and validate a contemporaneous risk score for use in a real-world clinical setting. Analyzing data from 1,001 patients recruited to the UK-PSC research cohort, we evaluated clinical variables for their association with 2-year and 10-year outcome through Cox-proportional hazards and C-statistic analyses. We generated risk scores for short-term and long-term outcome prediction, validating their use in two independent cohorts totaling 451 patients. Thirty-six percent of the derivation cohort were transplanted or died over a cumulative follow-up of 7,904 years. Serum alkaline phosphatase of at least 2.4 × upper limit of normal at 1 year after diagnosis was predictive of 10-year outcome (hazard ratio [HR] = 3.05; C = 0.63; median transplant-free survival 63 versus 108 months; P < 0.0001), as was the presence of extrahepatic biliary disease (HR = 1.45; P = 0.01). We developed two risk scoring systems based on age, values of bilirubin, alkaline phosphatase, albumin, platelets, presence of extrahepatic biliary disease, and variceal hemorrhage, which predicted 2-year and 10-year outcomes with good discrimination (C statistic = 0.81 and 0.80, respectively). Both UK-PSC risk scores were well-validated in our external cohort and outperformed the Mayo Clinic and aspartate aminotransferase-to-platelet ratio index (APRI) scores (C statistic = 0.75 and 0.63, respectively). Although heterozygosity for the previously validated human leukocyte antigen (HLA)-DR*03:01 risk allele predicted increased risk of adverse outcome (HR = 1.33; P = 0.001), its addition did not improve the predictive accuracy of the UK-PSC risk scores. Conclusion: Our analyses, based on a detailed clinical evaluation of a large representative cohort of participants with PSC, furthers our understanding of clinical risk markers and reports the development and validation of a real-world scoring system to identify those patients most likely to die or require liver transplantation.

来源:Hepatology,查看原文。版权归原作者所有。

引用

  1. Goode EC, Clark AB, Mells GF, et al. Factors Associated With Outcomes of Patients With Primary Sclerosing Cholangitis and Development and Validation of a Risk Scoring System. Hepatology. 2019. PMID: 30566748. doi:10.1002/hep.30479

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。